Clinical Trial Update: A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

A study is evaluating C-CAR031 for Glypican-3 positive advanced/recurrent hepatocellular carcinoma. It spans Phase 1 and Phase 2 and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• C-CAR031

Snippet

Sponsor: Shanghai AbelZeta Ltd. | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING